1. Niaspan(ER niacin) sells for $1 billion. its usage would be curtailed by doctor considering adverse event risk of stroke
2. AMR101 is ONLY drug to have proven benefits over CV outcomes in a combotheraypy with statin. Niaspan had hopes via AINM-HIGH..but that is gone now. We know fibrates have fared poorly on this regard
Market value of AMR101 would further increase with this news
Market Data 
Markets 
AI
